Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen: https://hdl.handle.net/10419/195065 
Erscheinungsjahr: 
2019
Schriftenreihe/Nr.: 
ZEW Discussion Papers No. 19-011
Verlag: 
ZEW - Leibniz-Zentrum für Europäische Wirtschaftsforschung, Mannheim
Zusammenfassung: 
This paper is concerned with exploring the implications of replicability issues over the medical innovation process. Each research setting is characterized by a specific level of replicability, variability increasing with the complexity of the testing settings. The study introduces new measures to quantify the research efforts across different medical experimental settings. Doing so allows to map the dynamics of knowledge along the medical R&D spectrum and over time. The lack of replicability of experiments was overcome by recombining technological knowledge coming from distinct uses (laboratory tool and other medical applications) with clinical insights. The citation analysis suggests that science, technology, and clinical learning interact strongly and have an uneven importance over time. The study stresses the importance of economics of scope between experimenting and technology developments. In this process, a new type of chemotherapy emerged without a centralized institution governing the testing effort. Research and innovation policy implications are discussed.
Schlagwörter: 
medical innovation
knowledge translation
replication
instrumentation
JEL: 
I12
O31
D83
D85
Dokumentart: 
Working Paper

Datei(en):
Datei
Größe
790.59 kB





Publikationen in EconStor sind urheberrechtlich geschützt.